Baxter International Beheer
Beheer criteriumcontroles 3/4
De CEO Baxter International is Joe Almeida, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.79M, bestaande uit 9.4% salaris en 90.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde $ 20.57M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 4.8 jaar.
Belangrijke informatie
Joe Almeida
Algemeen directeur
US$13.8m
Totale compensatie
| Percentage CEO-salaris | 9.4% |
| Dienstverband CEO | 8.8yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 2.1yrs |
| Gemiddelde ambtstermijn bestuur | 4.8yrs |
Recente managementupdates
Recent updates
Is Baxter International Inc. (NYSE:BAX) Trading At A 49% Discount?
Sep 05
Baxter- Reiterating Our Buy Rating After A Promising Q2
Aug 07Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.29
Aug 07Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
Jul 23Baxter: Why Investors Should Take Advantage Of The Low Valuation
Jul 16Little Excitement Around Baxter International Inc.'s (NYSE:BAX) Revenues
Jul 12Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 30Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
May 14Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 08Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
Nov 27Is Baxter International (NYSE:BAX) A Risky Investment?
Oct 27Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital
Sep 21Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Aug 23Dividend Challengers Review: Baxter International
Aug 14Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29
Jul 25Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet
Jul 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture
Jun 07Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 19Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 05Baxter International Inc.'s (NYSE:BAX) Intrinsic Value Is Potentially 26% Above Its Share Price
Apr 24Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$157m |
| Mar 31 2024 | n/a | n/a | -US$38m |
| Dec 31 2023 | US$14m | US$1m | -US$76m |
| Sep 30 2023 | n/a | n/a | US$225m |
| Jun 30 2023 | n/a | n/a | -US$3b |
| Mar 31 2023 | n/a | n/a | -US$3b |
| Dec 31 2022 | US$14m | US$1m | -US$3b |
| Sep 30 2022 | n/a | n/a | -US$3b |
| Jun 30 2022 | n/a | n/a | US$876m |
| Mar 31 2022 | n/a | n/a | US$992m |
| Dec 31 2021 | US$16m | US$1m | US$1b |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$1b |
| Mar 31 2021 | n/a | n/a | US$1b |
| Dec 31 2020 | US$16m | US$1m | US$1b |
| Sep 30 2020 | n/a | n/a | US$911m |
| Jun 30 2020 | n/a | n/a | US$924m |
| Mar 31 2020 | n/a | n/a | US$991m |
| Dec 31 2019 | US$14m | US$1m | US$1b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$16m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$1b |
| Jun 30 2018 | n/a | n/a | US$795m |
| Mar 31 2018 | n/a | n/a | US$840m |
| Dec 31 2017 | US$15m | US$1m | US$609m |
Compensatie versus markt: De totale vergoeding ($USD 13.79M ) Joe } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.86M ).
Compensatie versus inkomsten: De vergoeding van Joe is gestegen terwijl het bedrijf verliesgevend is.
CEO
Joe Almeida (62 yo)
8.8yrs
Tenure
US$13,786,671
Compensatie
Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board | 8.8yrs | US$13.79m | 0.11% $ 20.6m | |
| Executive VP | 1.1yrs | US$5.37m | 0% $ 0 | |
| Executive VP & Group President of Medical Products and Therapies | 1.7yrs | US$4.86m | 0.031% $ 5.8m | |
| Executive VP & Group President of Pharmaceuticals | 2.3yrs | US$3.87m | 0.0024% $ 434.7k | |
| Executive VP & Group President of Kidney Care | 1.4yrs | US$9.64m | 0.0046% $ 841.7k | |
| Senior VP and Chief Medical & Scientific Officer | 1.8yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Information Officer | less than a year | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP & General Counsel | 2.6yrs | US$5.66m | 0.0018% $ 333.4k | |
| Senior Vice President | no data | geen gegevens | geen gegevens | |
| Executive VP & Chief Human Resources Officer | 7.5yrs | US$4.14m | 0.037% $ 6.8m | |
| Executive VP & Chief Supply Chain Officer | 4.8yrs | geen gegevens | 0.0036% $ 663.0k |
2.1yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board | 8.8yrs | US$13.79m | 0.11% $ 20.6m | |
| Independent Director | 1.3yrs | US$197.82k | 0.0018% $ 327.8k | |
| Chairman Emeritus | 8.8yrs | US$17.88m | geen gegevens | |
| Independent Director | 2.5yrs | US$349.64k | 0.0026% $ 478.9k | |
| Independent Director | 7.8yrs | US$373.98k | 0.0055% $ 1.0m | |
| Independent Director | 5.8yrs | US$364.98k | 0.0042% $ 771.7k | |
| Independent Director | 2.9yrs | US$363.00k | 0.0028% $ 515.7k | |
| Independent Director | 7.8yrs | US$367.31k | 0.0044% $ 814.0k | |
| Lead Independent Director | 2.5yrs | US$382.31k | 0.0026% $ 478.9k | |
| Independent Director | 3.8yrs | US$357.00k | 0.0032% $ 587.5k | |
| Independent Director | 1.4yrs | US$226.35k | 0.0019% $ 355.5k | |
| Independent Director | 5.8yrs | US$352.98k | geen gegevens |
4.8yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).